Clinical significance of post-progression survival in lung cancer

about

Correlations Between mRNA Levels of Centrosomal Protein 55 (CEP55) and Clinical Features of Patients with Lung Cancer.Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study

P2860

Q55080656-3C4A3117-FAF6-41C4-920F-0F5A8E86CC57 Q58732719-4D30A076-BDCD-473B-83A7-A23797D35D54

P2860

Clinical significance of post-progression survival in lung cancer

Item

http://www.wikidata.org/entity/Q38669447

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical significance of post-progression survival in lung cancer

@en

type

Item

label

Clinical significance of post-progression survival in lung cancer

@en

prefLabel

Clinical significance of post-progression survival in lung cancer

@en

P1476

Clinical significance of post-progression survival in lung cancer

@en

P2093

Koichi Minato

http://www.w3.org/2001/XMLSchema#string

Kyoichi Kaira

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review

Cancer statistics, 2012

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.

Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.

General and statistical hierarchy of appropriate biologic endpoints.

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.

Detecting an overall survival benefit that is derived from progression-free survival

P304

379-386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1111/1759-7714.12463

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hisao Imai

P5008

ScienceSource

P577

2017-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28627767

http://www.w3.org/2001/XMLSchema#string

P921

lung small cell carcinoma

non-small-cell lung carcinoma

lung cancer

P932

5582459

http://www.w3.org/2001/XMLSchema#string

Clinical significance of post-progression survival in lung cancer

about

P2860

P2860

Clinical significance of post-progression survival in lung cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932